1. Overview
  2. All Stocks
  3. Firefly Neuroscience, Inc.

Firefly Neuroscience (AIFF.US) – Sell Signal: Rating and Stock Analysis 2026/2027

0.00
Analysis framework by , founder of TradeDesk · Data: EODHD, insider trades from SEC Form 4 filings · Updated
Share this analysis:

No analysts currently cover Firefly Neuroscience with a public price target. We add the price target automatically as soon as at least one analyst publishes a rating. Until then, use the technical analysis and the key figures below.

About Firefly Neuroscience – Software - Application

Firefly Neuroscience, Inc., an artificial intelligence company, develops, markets, and distributes medical devices and technologies that allow high-resolution visualization and evaluation of the complex neurophysiological interconnections of the human brain in North America. The company offers the Evoke System, a system used to perform electroencephalographic (EEG) and event-related potential (ERP) assessments, which are analyzed by its cloud-based platform and returned as structured reports designed to support clinical decision-making for various diseases, including depression, anxiety, ADHD, PTSD, MCI, dementia, Parkinson's disease, bipolar disorder, schizophrenia, schizoaffective disorder, ASD, and traumatic brain injury. It serves clinicians. Firefly Neuroscience, Inc. was founded in 2006 and is based in Kenmore, New York. Read more about the company

Key Figures for Firefly Neuroscience

$16.0M Market cap
$1.8M Revenue
Software - Application Industry
- P/E
8.90 P/S
1.23 P/B
United States Listed on exchange
fireflyneuro.com Website
Technology Sector

What kind of stock is Firefly Neuroscience?

Speculative stock

Firefly Neuroscience is classified as a speculative stock.

Score Overview for Firefly Neuroscience

💰 Value Score 28/100 (Low)
⭐ Quality Score 12/100 (Very Low)
🚀 Momentum Score 10/100 (Very Low)
📊 Total Score 16/100

⚠️ 4 red flags identified 3 critical

Our analysis has identified 4 potential risk factors in Firefly Neuroscience that investors should be aware of.

🚨 High debt: The debt-to-equity ratio is 1,000% – the company carries considerably more debt than equity, which raises the financial risk.
⚠️ Weak financial health: The Piotroski score is only 3/9 – the company shows signs of weakened profitability, liquidity or capital structure.
🚨 Weak balance sheet (elevated risk): Altman Z2 is -15.61 – the balance sheet is measurably weaker than average. This is a risk signal based on the numbers, not a bankruptcy prediction.
🚨 Negative return on equity: ROE is -68.1% – the company is generating a negative return for shareholders.

📈 Valuation

The P/S ratio is 8.9 (high — the market pays a premium for the revenue). The P/B ratio is 1.2.

🏦 Financial Health

The Piotroski score is 3 out of 9 — weak financial health, be careful. Altman Z2 is -15.61 (weak balance sheet — elevated risk). The debt-to-equity ratio (D/E) is 1,000.0% — high debt, which raises the risk.

🚀 Momentum & Short Interest

Short interest is 7.42% — elevated, some investors are betting on a decline.

↑ Back to navigation

Firefly Neuroscience Short Selling 2026: 7.4% Sold Short

High short interest: 7.4% of the free float
Short % of free float
7.4%
Assessment
High short interest
Short squeeze risk
Moderate
Data source
EODHD
Reported about twice a month
The stock has a high share of short selling. Between 5-10% of the freely traded shares are sold short, which suggests some investors are betting on falling prices. Positive surprises can lead to a moderate short squeeze.

What does this mean for you as an investor?
A short interest of 7.4% means that 7.4% of the freely traded shares in Firefly Neuroscience have been borrowed and sold by investors betting on falling prices.

The next potential catalyst is the earnings report on Nov 11, 2026. With a short interest of 7.4%, the report can trigger considerable volatility.

Short interest comes from our data provider EODHD. The figure is reported about twice a month; we check it every trading day.
Short Interest Scale
0% 2% 5% 10% 20%+
Low Moderate High Very High Extreme
▲
7.4%

↑ Back to navigation

When Does Firefly Neuroscience Report Earnings – Next Date: Nov 11, 2026

The next earnings report from Firefly Neuroscience is scheduled for November 11, 2026. This report covers the third quarter (Q3), which ended on September 30, 2026.



↑ Back to navigation

Technical Analysis of Firefly Neuroscience 2026 – Signal: Sell

Overall Technical Signal: Sell

Based on trend analysis (SMA50/SMA200) and MACD trend (positive/negative on a daily + weekly basis). Updated October 18, 2026.

Trend Analysis of Firefly Neuroscience, Inc.

Firefly Neuroscience, Inc. is in a short-term downtrend. The price of $1.02 is 21.7% below the 20-day average ($1.30). Medium term, the picture is negative: the price is 13.5% below the 50-day average ($1.18). Long term, the stock is 25.5% below the 200-day average ($1.37), which signals a long-term downtrend.

Death Cross: The 50-day average (1.18) is below the 200-day average (1.37), which is a classic bearish signal for Firefly Neuroscience, Inc..

Is Firefly Neuroscience, Inc. overbought or oversold?

Firefly Neuroscience, Inc. has an RSI of 39.9. The stock sits in the lower part of the neutral zone, which points to weak momentum without being oversold.

MACD Analysis for Firefly Neuroscience, Inc.

Daily MACD: MACD is negative (-0.038), which means the short-term trend is bearish (the 12-day EMA is below the 26-day EMA). MACD is below the signal line (0.008) by 0.046, which confirms growing negative momentum in the downtrend.

Weekly MACD: MACD5 is negative (-0.112), which indicates a broader bearish long-term trend. MACD5 is above the signal line (-0.139) by 0.027, which suggests the negative long-term momentum is fading – a bigger trend reversal could be ahead.

Overall MACD assessment: Both the daily and weekly trend are bearish (MACD negative). However, momentum shows signs of improving on a weekly basis – a potential trend reversal could be ahead, but it is not confirmed yet.

Risk Profile for Firefly Neuroscience, Inc.

Firefly Neuroscience, Inc. has an annual standard deviation of 0.0%, which classifies the stock as Conservative. Price swings are limited, and the stock suits conservative investors.

Overall Technical Conclusion for Firefly Neuroscience, Inc.

Trend: Neutral/mixed.

MACD trend (zero line): Daily bearish (-0.038). Weekly bearish (-0.112).

MACD momentum (signal): Daily falling. Weekly rising.

RSI: 39.9 – neutral.

Technical signal: Sell

The trend is negative and MACD is below the zero line, which confirms the bearish momentum. Consider reducing the position or setting a stop-loss.

↑ Back to navigation

Frequently Asked Questions About Firefly Neuroscience stock in 2026

Should you buy Firefly Neuroscience stock now?
No, the technical signal for Firefly Neuroscience is currently Sell. Firefly Neuroscience trades at $0.00 as of Oct 18, 2026. The technical analysis shows the following: MACD is negative (bearish trend) at -0.038 with falling momentum (signal: 0.008); RSI is at 39.9 (neutral zone). This is a technical observation based on current data, not investment advice.
What is the price target for Firefly Neuroscience stock?
There is currently no active analyst price target for Firefly Neuroscience.
Is Firefly Neuroscience a dividend stock?
No, Firefly Neuroscience does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Firefly Neuroscience stock?
Firefly Neuroscience is rated as a stock in the risk category Conservative. the annual standard deviation is 0.0%, which classifies the stock as Conservative.
Is Firefly Neuroscience overvalued?
Firefly Neuroscience has the following valuation ratios: a P/S ratio of 8.9, a P/B ratio of 1.2.
Is Firefly Neuroscience overbought?
No, Firefly Neuroscience is not overbought. RSI is at 39.9 (neutral zone). The technical indicators show: RSI is at 39.9 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, MACD is negative with falling momentum (bearish).
When is the next Firefly Neuroscience earnings report?
Firefly Neuroscience reports its next earnings on November 11, 2026. The stock currently trades at $0.00.
Is Firefly Neuroscience shorted?
Yes, Firefly Neuroscience is shorted with 7.4% of the free float sold short. This is a high level of short selling, which suggests some investors are betting on falling prices. Positive surprises can lead to a moderate short squeeze. The figure comes from our data provider EODHD, is reported about twice a month, and we check it every trading day.
Are insiders buying Firefly Neuroscience stock?
There is currently no registered insider trading for Firefly Neuroscience.
Is Firefly Neuroscience a good stock?
Based on our total score, Firefly Neuroscience is rated as a disastrous stock with a total score of 16 out of 100. The stock scores very low on value, quality and momentum – it is among the worst in our database. The score is made up of Value: 28/100, Quality: 12/100, Momentum: 10/100. Whether now is the time to buy is a separate question: the technical signal is Sell. Whether Firefly Neuroscience is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Firefly Neuroscience stock?
The outlook for Firefly Neuroscience based on current data: the next earnings report is due on Nov 11, 2026, which can move the price. Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Firefly Neuroscience stock moving?
Firefly Neuroscience is moving right now. The technical indicators show: MACD is negative with falling momentum (bearish signal); short interest is 7.4% (high – many are betting on a decline). For the latest context, see our technical analysis and insider section above.
How high can Firefly Neuroscience go?
There is currently no active analyst price target for Firefly Neuroscience. The stock has traded between $0.62 and $3.15 over the last 52 weeks. The price is 100.0% below the 52-week high, which can indicate potential if the underlying fundamentals are intact. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Firefly Neuroscience fall?
We lack enough history to give a specific floor for Firefly Neuroscience. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Firefly Neuroscience do?
Firefly Neuroscience, Inc., an artificial intelligence company, develops, markets, and distributes medical devices and technologies that allow high-resolution visualization and evaluation of the complex neurophysiological interconnections of the human brain in North America. T... The company belongs to the Technology sector, more specifically the Software - Application industry, is headquartered in United States, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Firefly Neuroscience as an investment.
Did Firefly Neuroscience raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Firefly Neuroscience. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history above.
Is Firefly Neuroscience making money or losing money?
We have no current profitability data for Firefly Neuroscience. See the latest report in the earnings history above.
Can Firefly Neuroscience go bankrupt?
The bankruptcy risk of Firefly Neuroscience is rated as elevated. Altman Z2 (a model for assessing financial distress) is -15.61 — that places the company in the weak zone. This is a probability based on the numbers, not a verdict — bankruptcy is not imminent. But the balance sheet is measurably weaker than average, so watch the debt, liquidity and possible capital raises. The Piotroski score (financial health 0-9, higher is better) is 3 — which is weak. Debt relative to equity is 1,000% (high). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Firefly Neuroscience have a lot of debt?
Yes, Firefly Neuroscience has elevated debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 1,000%. For the technology sector, anything above 120% counts as elevated — that raises the financial risk, especially if interest rates rise or earnings fall. Tech companies are usually asset-light and need little borrowed capital — anything below 60% counts as low in this sector. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.
↑ Back to navigation

Other Stocks in Technology

Compare Firefly Neuroscience with other stocks in the technology sector. Click a stock to see its technical analysis, insider trading and key figures.

See all 208 stocks in the Technology sector

Explore More